ENXTPA:DIMLife Sciences
Sartorius Stedim Biotech (ENXTPA:DIM) Margin Expansion Reinforces Bullish Earnings Narrative
Sartorius Stedim Biotech (ENXTPA:DIM) has just opened Q1 2026 earnings season with a reference point of Q4 2025 revenue of €772.2 million and basic EPS of €0.49, supported by trailing 12 month revenue of about €3.0 billion and EPS of €2.73. Over recent quarters the company has seen quarterly revenue move between €655.4 million and €772.2 million, while basic EPS ranged from €0.26 to €0.88. This provides a clear view of how earnings power has tracked the top line. With trailing net profit...